Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
about
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismPharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesVU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo EfficacyModulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration.Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingEffects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma.Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.Development of allosteric modulators of GPCRs for treatment of CNS disordersGlutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.Therapeutic potential of metabotropic glutamate receptor modulators.N-acetylcysteine protects against apoptosis through modulation of group I metabotropic glutamate receptor activity.Memory and motor coordination improvement by folic Acid supplementation in healthy adult male ratsMetabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.Glutamate receptors as therapeutic targets for Parkinson's disease.PET brain kinetics studies of (11)C-ITMM and (11)C-ITDM,radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsTherapeutic potential of targeting glutamate receptors in Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseaseMolecular imaging of levodopa-induced dyskinesias.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Motor disturbances and thalamic electrical power of frequency bands' improve by grape seed extract in animal model of Parkinson's disease.Metabotropic glutamate receptors for Parkinson's disease therapy.The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.Antidyskinetic Treatment with MTEP Affects Multiple Molecular Pathways in the Parkinsonian Striatum.Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease.L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats
P2860
Q24614102-7098413B-BF71-4415-8265-77477D8FE7B2Q26852311-84A3D230-C837-476F-A16C-A423CDDB0096Q30366876-4B485269-D796-4CB7-A147-B0AF39A9567EQ30575965-742F506F-4531-45E3-A6EB-1A5FE3F925B3Q33428476-E2D26F6A-787C-4235-9C9A-DB79A781B28AQ33825775-593853DB-17A5-4D1B-A259-550CAB94910FQ34174680-6F9900E0-A9EA-453B-BDDC-439362A4550EQ34269340-E5DC688C-145B-435D-BCC2-6D71F02B309FQ34373958-862D6DE1-0B95-43BD-98F3-A29A2D1288BFQ35124773-8DD3770F-2794-410E-8140-6D8B91AEBA54Q35778704-0D7BE235-B024-40FC-91E1-CBB292779B17Q35839823-F954EA2E-87C0-44AB-B19D-D8F798BBBA3BQ36821905-4530771D-5762-48DB-82BF-DFABE6CD5FD5Q37384351-21A200E4-FDDB-4F1D-B2D4-CAF79545A38BQ37585401-5B65C22C-4F39-4F44-8864-905C980F756BQ37722897-7FE13FC6-3475-4F53-A7F0-2B6DD883BEE2Q37924629-E94686F8-4878-49A7-B841-645E5040375EQ38056852-1CB17C73-0DA6-437D-88A0-266AA57C2A74Q38092819-05B78926-0071-4A40-BC67-4C6611287D2BQ38156760-0D5D505C-F5AE-4EEF-B3B3-27CF836C022CQ38190016-1F815A5A-0795-4AF3-BF94-39158A5CFD76Q38218083-C81281C2-9911-44C0-B00E-A1E22FA6D9FEQ38355582-DB2E92A9-F588-43E6-A547-C6B9C8794F7DQ38660240-774BC919-C12A-427E-BAFA-238A782BEB1DQ39324877-3F19A777-A041-400F-ABAE-AB605242B3A2Q41498599-C955950A-1E7A-41C8-A135-1D7D703124BFQ41818450-61453582-5F6C-4D8B-A488-568C5B9FD7B8Q42647545-368FABBC-1A29-4B30-8765-E105B91F7AA4Q42777922-276AF99A-83FF-4BF0-B3A5-A2B93F8F59D5Q43067885-BB79F465-56DD-4BD6-967E-BC5A1DB44E15Q45075694-0E6546FB-DF8A-4CB1-953C-0DD04D4C7F1CQ46428813-EE658D5B-C9A1-43EE-A378-F9645AE53F2FQ47137434-657FCE4F-9ACA-46F6-BBCA-31D66024D6A9Q47344907-41456ACD-526F-4AA3-97FD-7EEF658F1E7CQ48483960-D29E9EBF-7537-427C-84E5-DD1A26107F13Q52665081-B74B65D2-DAE8-4020-A5FD-0180290AA551Q59136653-F19B6CE2-C460-4127-8D4A-9170B7B27840
P2860
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Effects of group I metabotropi ...... models of Parkinson's disease.
@en
Effects of group I metabotropi ...... models of Parkinson's disease.
@nl
type
label
Effects of group I metabotropi ...... models of Parkinson's disease.
@en
Effects of group I metabotropi ...... models of Parkinson's disease.
@nl
prefLabel
Effects of group I metabotropi ...... models of Parkinson's disease.
@en
Effects of group I metabotropi ...... models of Parkinson's disease.
@nl
P2093
P1476
Effects of group I metabotropi ...... models of Parkinson's disease.
@en
P2093
Andrzej Dekundy
Daniela Schaefer
M Angela Cenci
Malgorzata Pietraszek
Wojciech Danysz
P304
P356
10.1016/J.BRAINRESBULL.2005.12.009
P577
2006-01-25T00:00:00Z